Physician profile
Thomas Harris
NPI 1346259835
$10,862.93
in general payments reported to CMS, 2019-2025
41 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $386 · 2021: $964 · 2022: $1,253 · 2023: $2,353 · 2024: $2,267 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,018 · Education: $8.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,018.12 |
| Education | $8.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,407.42 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $2,278.93 | 2019-2025 | |
| Novo Nordisk INC | $1,424.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $980.07 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $827.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $490.32 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Allergan, INC. | $297.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.11 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $206.02 | 2019 | |
| Pfizer INC. | $168.51 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $135.30 | 2025 | Voquezna |
| Abbott Laboratories | $134.29 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $128.29 | 2021-2025 | |
| Exact Sciences Corporation | $123.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $114.08 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.